Trial: 201712157

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39) with Newly Diagnosed Precursor B-Cell ALL



Principal Investigator

Uy, Geoffrey

Disease Site

Acute Lymphocytic Leukemia (ALL); Lymphoid Leukemia

Learn more about this study at: